rs876659681
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000249.4(MLH1):c.2070_2071insTT(p.Ile691LeufsTer93) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000249.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:2
- -
- -
not provided Pathogenic:2
- -
Frameshift variant predicted to result in protein truncation in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Observed in at least one individual with a personal history of colon cancer who underwent multi-gene panel testing (PMID: 28135145); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 28135145) -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.2070_2071insTT pathogenic mutation, located in coding exon 18 of the MLH1 gene, results from an insertion of two nucleotides at position 2070, causing a translational frameshift with a predicted alternate stop codon (p.I691Lfs*93). This frameshift, which occurs at the 3' terminus of MLH1, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 66 amino acids of the protein in addition to elongating the protein by 26 amino acids. Structural analysis shows that this alteration perturbs a known functional domain responsible for binding to and stabilizing PMS2 and removes a cysteine residue shown to be involved in metal binding as part of a functional domain in PMS2 (Ambry internal data; Mohd AB et al. DNA Repair (Amst.) 2006 Mar;5(3):347-61; Smith CE et al. PLoS Genet. 2013 Oct;9(10):e1003869). The vast majority of tumors from mutation carriers demonstrated microsatellite instability and loss of MLH1 on immunohistochemical staining. There was also complete segregation with Lynch-related cancers in all informative families, nearly all of whom fulfilled Amsterdam criteria (Caluseriu O et al. J. Med. Genet. 2004 Mar;41(3):e34; Ambry internal data). The c.2070_2071insTT mutation has been detected in multiple individuals whose families meet Amsterdam criteria, and whose tumors show microsatellite instability and/or absence of MLH1 and PMS2 on immunohistochemical staining (Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
This variant inserts 2 nucleotides in exon 18 of the MLH1 gene, creating a frameshift predicted to result in an alternate stop codon. This variant is expected to escape nonsense mediated decay, and impacts the last 66 amino acids of the MLH1 protein and extends the protein by 26 amino acids. Although functional studies have not been reported for the variant, it is expected to disrupt the PMS2/MLH3/PMS1 interacting domain (PMID: 12799449, 16338176, 20533529). This variant has been reported in individuals affected with Lynch syndrome (ClinVar SCV000276394.6) and in an individual affected with colorectal cancer with family history and clinical features suspect of Lynch syndrome (PMID: 28135145). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MLH1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Lynch syndrome Pathogenic:1
The c.2070_2071insTT (p.Ile691Leufs*93) variant of the MLH1 gene is located in exon 18, resulting in a premature translational stop codon (p.I691Lfs*93). This variant, which occurs at the 3' terminus of MLH1, is not expected to trigger nonsense-mediated mRNA decay. This variant impacts the last 66 amino acids of the protein and is expected to lead to elongation of the protein by 26 amino acids. This change is predicted to lead to a disrupted or non-functional MLH1 protein. Loss of function is a known mechanism of pathogenicity for MLH1 gene (PMID: 14635101, 15942939, 16955466, 33468175). This variant has been reported in individuals affected with Lynch syndrome (28514183) and in an individual affected with colorectal cancer with family history and clinical features suspect of Lynch syndrome (PMID: 28135145). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of function variants leading to alternate stop codon downstream of this variant have been interpreted as pathogenic (Variation ID: 418306, 2573270, 1069993). Clinvar contains an entry for this variant (variation ID 232298). Based on the available evidence the c.2070_2071insTT (p.Ile691LeufsTer93) variant of MLH1 is classified as pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change results in a frameshift in the MLH1 gene (p.Ile691Leufs*93). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 66 amino acid(s) of the MLH1 protein and extend the protein by 26 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MLH1-related conditions. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this MLH1 variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 1,370,736 individuals referred to our laboratory for MLH1 testing. ClinVar contains an entry for this variant (Variation ID: 232298). This variant disrupts a region of the MLH1 protein in which other variant(s) (p.Tyr750*, p.Lys732*, p.Ser726*) have been determined to be pathogenic (PMID: 10422993, 10923051, 25197397; internal data). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at